开拓药业-B(09939)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

09939 开拓药业-B

圣诞节休市 12-24 11:50:00

1.920

+0.000

0.00%

最高1.930	最低1.870	成交量20.00万
今开1.920	昨收1.920	日振幅3.13%
总市值9.58亿	流通市值9.58亿	总股本4.99亿
成交额38.04万	换手率0.04%	流通股本4.99亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"09939","market":"HK","secType":"STK","nameCN":"开拓药业-B","latestPrice":1.92,"timestamp":1766548200002,"preClose":1.92,"halted":0,"volume":200000,"delay":0,"floatShares":499000000,"shares":499000000,"eps":-0.40002628150953373,"marketStatus":"圣诞节休市","change":0,"latestTime":"12-24 11:50:00","open":1.92,"high":1.93,"low":1.87,"amount":380430,"amplitude":0.03125,"askPrice":1.92,"askSize":2000,"bidPrice":1.9,"bidSize":9500,"shortable":0,"etf":0,"ttmEps":-0.4285445071386358,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1766971800000},"marketStatusCode":7,"adr":0,"listingDate":1590076800000,"exchange":"SEHK","adjPreClose":1.92,"openAndCloseTimeList":[[1766539800000,1766548800000]],"volumeRatio":1.0592200287093274,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/09939","defaultTab":"news","newsList":[{"id":"2594286909","title":"国信证券：美国医药供应链新规出台 关注CXO板块投资机会","url":"https://stock-news.laohu8.com/highlight/detail?id=2594286909","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2594286909?lang=zh_cn&edition=full","pubTime":"2025-12-25 09:40","pubTimestamp":1766626821,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，国信证券发布研报称，美国国会近日通过2026财年国防授权法案，其中纳入修订版《生物安全法案》相关条款，中国创新药产业长期竞争力仍受看好。建议关注CXO板块，并留意创新药海外临床进展。国信证券主要观点如下：《生物安全法案》获参、众议院通过，关注CXO板块投资机会美国时间12月17日，美国参议院以77票赞成、20票反对的表决结果，通过2026财年国防授权法案。法案后续将提交白宫，待美国总统签署生效。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1385747.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["002736","BK0188","CXO","BK1515","BK0276","BK0183","159938","09939","BK0028","BK1161","BK1574"],"gpt_icon":0},{"id":"2594003114","title":"加科思之后，下一个爆点","url":"https://stock-news.laohu8.com/highlight/detail?id=2594003114","media":"瞪羚社","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2594003114?lang=zh_cn&edition=full","pubTime":"2025-12-24 21:40","pubTimestamp":1766583658,"startTime":"0","endTime":"0","summary":"上方“瞪羚社”即刻关注并加入社群聚焦高成长公司，100000+投资菁英共同关注加科思前几天的BD惊艳了整个医药界，pan-Kras抑制剂也因此而一战成名。之后，它陆续发布了二期临床数据。目前来看，劲方医药在恶病质适应症上已经走向了下一代双抗的布局。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251224231936a473e6ae&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251224231936a473e6ae&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1574","09939","BK1161","01167"],"gpt_icon":0},{"id":"2593347915","title":"泓博医药最新公告：股东泓博智源（香港）医药技术有限公司拟询价转让697.93万股股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2593347915","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593347915?lang=zh_cn&edition=full","pubTime":"2025-12-24 19:00","pubTimestamp":1766574023,"startTime":"0","endTime":"0","summary":"泓博医药(301230.SZ)公告称，公司持股5%以上的股东泓博智源（香港）医药技术有限公司计划通过询价转让方式，转让其持有的697.93万股公司股份，占公司总股本的5.00%，占剔除公司回购专用账户后的总股本的5.07%。转让原因为自身资金需求。本次询价转让不通过集中竞价交易或大宗交易方式进行，受让方通过询价转让受让的股份在受让后6个月内不得转让。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025122400031582.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1161","159938","BK1574","09939","BK0216","BK1515","301230"],"gpt_icon":0},{"id":"2593047310","title":"健康之路(02587)附属拟出售福建健宸医药有限公司51%的股权","url":"https://stock-news.laohu8.com/highlight/detail?id=2593047310","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593047310?lang=zh_cn&edition=full","pubTime":"2025-12-24 17:30","pubTimestamp":1766568608,"startTime":"0","endTime":"0","summary":"智通财经APP讯，健康之路 公布，于2025年12月24日，公司的全资附属公司浙江健康之路科技集团有限公司拟向肖靖女士出售福建健宸医药有限公司51%的股权，总代价为人民币167.79万元。出售公司因于2023年末流感疫情爆发期间囤积奥司他韦而取得收入暂时性增长。随着疫情的消退，出售公司作为单一产品存货的药品批发商的局限性变得显而易见。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1385519.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["09939","159938","BK1515","BK1574","BK1219","02587","BK1161"],"gpt_icon":0},{"id":"2593422587","title":"新股消息 | 新济医药递表港交所","url":"https://stock-news.laohu8.com/highlight/detail?id=2593422587","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593422587?lang=zh_cn&edition=full","pubTime":"2025-12-24 15:13","pubTimestamp":1766560418,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，据港交所12月24日披露，广州新济医药股份有限公司向港交所主板递交上市申请书，国泰海通为其独家保荐人。新济医药的首项核心产品盐酸右美托咪定微针贴剂乃为儿童患者及成人患者的术前镇静而开发。截至2025年12月18日，盐酸右美托咪定微针贴剂已于中国进入用于儿童患者的IIa期临床试验。NMPA已批准开始用于成人患者的II期临床试验，而相关临床试验预计于2026年第一季开始。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1385413.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1515","09939","159938","HEXmain","BK1574","BK1161"],"gpt_icon":0},{"id":"2594409233","title":"医药行业洗牌加剧，药企年末迎来大整合","url":"https://stock-news.laohu8.com/highlight/detail?id=2594409233","media":"动脉网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2594409233?lang=zh_cn&edition=full","pubTime":"2025-12-24 14:03","pubTimestamp":1766556180,"startTime":"0","endTime":"0","summary":"2025年以来医药企业整合重组频繁，年末又迎收购潮。12月22日，日本盐野义决定收购田边制药新公司100%股份，此前其已发起多次收购；12月15日，复星医药拟14.12亿元收购绿谷医药控股权，加码中枢神经系统诊疗领域布局；12月14日，佐力药业3.56亿元收购未来医药多种微量元素注射液资产组，优化产品结构；国内药企年末动作频繁，11月石药创新11亿元收购巨石生物29%股权，海正药业挂牌子公司全部股权，12月广州医药5.01亿元受让。业内认为，这些交易折射出国内医药行业从“规模扩张”转向“提质增效”、分化加剧、资源向头部与创新集中。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251224141434a471f744&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251224141434a471f744&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["IE00BZ08YR35.GBP","LU0072913022.USD","BK1574","LU1960683339.HKD","BK1161","BK1521","LU1226287529.USD","IE00BZ08YT58.USD","HK0000165453.HKD","LU0315179316.USD","LU1008478684.HKD","LU1226287875.USD","LU1328277881.USD","LU0140636845.USD","BK1515","IE00B031HY20.USD","LU1226288170.HKD","LU1807302812.USD","IE00BZ08YS42.EUR","LU0067412154.USD","IE0008368742.USD","LU0501845795.SGD","LU1152091754.HKD","LU1993786604.SGD","LU1226288253.USD","01093","LU0326950275.SGD","LU1226287792.SGD","LU1813983027.USD","09939","IE0008369823.USD","LU1152091168.USD","BK1191","LU1951186391.HKD","IE00B543WZ88.USD","IE00B5MMRT66.SGD","SG9999004220.SGD","LU0880133367.SGD","LU2039709279.SGD","LU0314109678.HKD"],"gpt_icon":0},{"id":"2593444150","title":"医药巨头，突然暴涨","url":"https://stock-news.laohu8.com/highlight/detail?id=2593444150","media":"中国基金报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593444150?lang=zh_cn&edition=full","pubTime":"2025-12-24 08:19","pubTimestamp":1766535577,"startTime":"0","endTime":"0","summary":"【导读】英伟达大涨超3%，诺和诺德暴涨7.3%，铜价超12000美元/盎司中国基金报记者储是隔夜美股市场，标普500指数创新高。英伟达领涨科技股，市值重回4.6万亿美元。继黄金、白银后，铜价也创下新高。标普500指数创新高美东时间12月23日（周二），美股盘中持续走强，三大指数均收涨，其中标普500指数收于新高。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202512243600135425.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202512243600135425.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1574","159938","BK1515","09939","BK1161"],"gpt_icon":0},{"id":"2593869497","title":"医药巨头年末杀疯了：25亿美元买渐冻症药物，10.6亿美元ADC出海","url":"https://stock-news.laohu8.com/highlight/detail?id=2593869497","media":"MedTrend医趋势","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593869497?lang=zh_cn&edition=full","pubTime":"2025-12-23 19:44","pubTimestamp":1766490240,"startTime":"0","endTime":"0","summary":"盐野义方面表示，预计该交易将于2026年4月1日或之后完成交割，交易完成后每年将为公司新增约7亿美元的全球销售额。根据官方披露，盐野义将以25亿美元的一次性付款方式收购Radicava相关业务，同时约定在“特定条件”下支付潜在的未来特许权使用费。交易交割后，Radicava业务单元将成为盐野义的全资子公司。","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/hk/2025-12-23/doc-inhcuyui5237827.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK4080","ADC","159938","BK1574","09939","BK4231","BK1515","BK1161"],"gpt_icon":0},{"id":"2593527423","title":"中集安瑞科向医药客户交付生物甲醇，中集世联达送“绿”上门","url":"https://stock-news.laohu8.com/highlight/detail?id=2593527423","media":"第一工程机械网","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593527423?lang=zh_cn&edition=full","pubTime":"2025-12-23 18:30","pubTimestamp":1766485800,"startTime":"0","endTime":"0","summary":"近日，中集安瑞科旗下中集绿能顺利完成生物基甲醇交付，为国内某生物医药企业提供高纯度绿色原料，标志着中集安瑞科正式打通生物基甲醇在生物医药领域的应用通道。中集安瑞科此次交付的生物基甲醇产品通过美国Beta实验室的放射性同位素碳C14检测，生物基碳含量达99.08%，源自广东湛江5万吨/年的生物甲醇工厂。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251223184820a46e971e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251223184820a46e971e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["03899","SG9999004220.SGD","LU0449515922.USD","LU0054450605.USD","BK1515","BK1574","LU0214875030.USD","LU0449509016.USD","LU2242644610.SGD","BK1161","BK1183","09939","BK1522"],"gpt_icon":0},{"id":"2593419490","title":"医药创新看中国：“一哥”恒瑞研发瞄定三大策略，构建全球竞争力","url":"https://stock-news.laohu8.com/highlight/detail?id=2593419490","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593419490?lang=zh_cn&edition=full","pubTime":"2025-12-23 17:15","pubTimestamp":1766481352,"startTime":"0","endTime":"0","summary":"“中国在创新药研发管线方面的规模已占全球的四分之一左右，每年开展的临床试验数量约3000项，这两项关键指标均处于世界前列。”全球医药交易市场也在见证中国力量的崛起。而在创新队列中，恒瑞作为龙头企业，始终占据着重要位置。恒瑞医药董事长孙飘扬在2025年研发日上表示，恒瑞始终坚持创新与国际化战略。这些数据表明中国创新药正从“跟随式创新”迈向“全球领跑”的新阶段。一举创下国内史上BD单笔交易规模最大纪录。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251223172225a46e4c97&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251223172225a46e4c97&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","BK1191","BK1574","LU0359201612.USD","09939","LU2543165471.USD","BK1515","LU0359201885.HKD","LU1023057109.AUD","01276","LU0359202008.SGD"],"gpt_icon":0},{"id":"2593499153","title":"每日卖空追踪 | 同源康医药-B 12月23日卖空量成交2500股，卖空比例为0.33%","url":"https://stock-news.laohu8.com/highlight/detail?id=2593499153","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593499153?lang=zh_cn&edition=full","pubTime":"2025-12-23 16:30","pubTimestamp":1766478630,"startTime":"0","endTime":"0","summary":"同源康医药-B北京时间12月23日，跌0.3%，卖空量成交2500股，较上一交易日减少89.13%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251223163422a6c51e62&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251223163422a6c51e62&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","BK1515","02410","BK1574","09939"],"gpt_icon":0},{"id":"2593494070","title":"HTI医药2025年12月第三周周报：行业高景气，持续关注创新药械产业链","url":"https://stock-news.laohu8.com/highlight/detail?id=2593494070","media":"海通国际","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593494070?lang=zh_cn&edition=full","pubTime":"2025-12-23 16:07","pubTimestamp":1766477237,"startTime":"0","endTime":"0","summary":"2025年12月第三周A股医药板块表现与大盘相当。2025年12月第三周上证综指上涨0.03%，SW医药生物下跌0.1%，涨跌幅在申万一级行业中排名第19位。截至2025年12月19日，医药板块相对于全部A股的溢价水平目前处于正常水平，当前相对溢价率70.1%。2025年12月第三周美股标普医疗保健精选行业+0.6%，同期标普500+0.1%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251223160731a6c4fe72&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251223160731a6c4fe72&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1515","HK0000252160.HKD","02487","LU2543165471.USD","01530","09939","01858","HK0000252152.HKD","09606","01276","HK0000500386.USD","02615","02359","02269","01801","06990","06078","BK1161","06160","BK1574"],"gpt_icon":0},{"id":"2593741940","title":"12月，石药集团、百济神州、百花村医药等一批药企已“换帅”","url":"https://stock-news.laohu8.com/highlight/detail?id=2593741940","media":"制药网","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593741940?lang=zh_cn&edition=full","pubTime":"2025-12-23 15:17","pubTimestamp":1766474250,"startTime":"0","endTime":"0","summary":"如在近期，石药集团、百济神州、百花村医药等一批药企就已纷纷宣布“换帅”。12月19日，石药集团公告宣布执行董事蔡磊接任董事会副主席、首席执行官。12月12日，药明巨诺发布公告，宣布一系列核心管理层及董事会架构调整。除了上述企业，在12月以来，恒瑞医药、康恩贝、南新制药、振东制药等也已发布过高管变动公告。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251223152053a46dc612&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251223152053a46dc612&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0315179316.USD","LU1008478684.HKD","LU0326950275.SGD","IE0008369823.USD","LU0140636845.USD","LU1152091754.HKD","BK1500","LU1226288170.HKD","09939","LU1960683339.HKD","BK1583","BK1588","06160","LU1152091168.USD","LU1951186391.HKD","BK1515","LU1969619763.USD","IE00BZ08YS42.EUR","BK1574","LU0072913022.USD","LU0359202008.SGD","IE00B5MMRT66.SGD","BK1161","LU1807302812.USD","LU0307460666.USD","LU1813983027.USD","01093","IE00B543WZ88.USD","IE00BZ08YR35.GBP","LU1226287529.USD","LU2039709279.SGD","LU0314109678.HKD","LU1328277881.USD","LU1023057109.AUD","LU0067412154.USD","BK1191","LU0359201612.USD","LU2328871848.SGD","LU0501845795.SGD","LU2543165471.USD","LU0359201885.HKD","SG9999004220.SGD","IE00B031HY20.USD","LU0880133367.SGD","LU1993786604.SGD","HK0000165453.HKD","IE00BZ08YT58.USD","LU0588546209.SGD","LU1719994722.HKD","01276"],"gpt_icon":0},{"id":"2593462888","title":"鹭燕医药：海南封关将助力医药产品跨境流通","url":"https://stock-news.laohu8.com/highlight/detail?id=2593462888","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593462888?lang=zh_cn&edition=full","pubTime":"2025-12-23 15:07","pubTimestamp":1766473639,"startTime":"0","endTime":"0","summary":"公司于2023年9月对海南鹭燕增资，将海南鹭燕的注册资本由3500万元增至1亿元，用于满足海南鹭燕经营发展及“鹭燕医药海南总部基地项目”建设需要。海南封关，将为公司医药产品跨境流通业务提供助力。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025122300018908.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1574","BK1515","09939","BK0250","159938","002788","BK1161"],"gpt_icon":0},{"id":"2593639194","title":"武汉又冲出一个医药IPO！60岁武大学霸带队","url":"https://stock-news.laohu8.com/highlight/detail?id=2593639194","media":"创业邦","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593639194?lang=zh_cn&edition=full","pubTime":"2025-12-23 11:23","pubTimestamp":1766460221,"startTime":"0","endTime":"0","summary":"翰思艾泰正在研发用于癌症及自身免疫疾病精准治疗的创新药，解决该领域未被满足的医疗需求。01湖北农村走出的IPO敲钟人现年60岁的张发明，出生在湖北天门石家河镇的一个普通农村家庭，16岁时考入武汉大学物理化学专业，是家中第一个走出乡村的大学生。以此为平台，张发明正式进军创新药研发。HX009是一款PD-1/SIRPα双功能抗体融合蛋白，其设计旨在同时阻断PD-1免疫抑制信号和CD47-SIRPα介导的免疫逃逸信号，从而协同激活T细胞和巨噬细胞，对抗肿瘤。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251223112437a6c409fc&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251223112437a6c409fc&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","09939","03378","BK1515","BK1535","BK1173","BK1574"],"gpt_icon":1},{"id":"2593452284","title":"创金合信医药消费股票A基金经理变动：刘迪不再担任该基金基金经理","url":"https://stock-news.laohu8.com/highlight/detail?id=2593452284","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593452284?lang=zh_cn&edition=full","pubTime":"2025-12-23 09:31","pubTimestamp":1766453489,"startTime":"0","endTime":"0","summary":"证券之星消息，2025年12月23日，创金合信医药消费股票（010585）发布公告，刘迪不再担任该基金基金经理，离任日期为2025年12月23日，变更后创金合信医药消费股票（010585）的基金经理为毛丁丁,皮劲松。截止2025年12月22日，创金合信医药消费股票净值为0.4562，较上一日下跌0.24%，近一年下跌7.78%。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025122300007577.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1161","09939","159938","BK1515","BK1574"],"gpt_icon":0},{"id":"2593459642","title":"复星医药拟14.12亿元控股绿谷医药，押注阿尔茨海默病新药后续研发","url":"https://stock-news.laohu8.com/highlight/detail?id=2593459642","media":"中访网数据","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593459642?lang=zh_cn&edition=full","pubTime":"2025-12-23 00:00","pubTimestamp":1766419200,"startTime":"0","endTime":"0","summary":"中访网数据上海复星医药（集团）股份有限公司近日发布公告，回复上海证券交易所关于其对外投资事项的监管工作函。核心信息显示，复星医药拟出资共计14.12亿元，通过受让股权及认购新增注册资本的方式，取得上海绿谷医药有限公司51%的控股权。此次交易的核心标的为绿谷医药旗下已暂停销售的阿尔茨海默病治疗药物甘露特钠胶囊。复星医药表示，此次收购旨在丰富其中枢神经系统疾病治疗领域的产品管线。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251223000126a46b26b0&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251223000126a46b26b0&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","09939","BK1574","BK1515","02196","BK1593","BK1191"],"gpt_icon":0},{"id":"2593894344","title":"启迪药业最新公告：证券简称拟变更为“古汉医药”","url":"https://stock-news.laohu8.com/highlight/detail?id=2593894344","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593894344?lang=zh_cn&edition=full","pubTime":"2025-12-22 18:49","pubTimestamp":1766400581,"startTime":"0","endTime":"0","summary":"启迪药业(000590.SZ)公告称，公司第十届董事会临时会议于2025年12月22日召开，会议审议通过《关于变更公司证券简称的议案》。公司证券简称将由“启迪药业”变更为“古汉医药”，并向深圳证券交易所提交证券简称变更申请。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025122200024941.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["159938","BK1515","000590","BK1574","BK1161","BK0122","161027","BK0239","09939"],"gpt_icon":0},{"id":"2593610044","title":"和誉-B(02256)：和誉医药CSF-1R抑制剂贝捷迈®获中国NMPA批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2593610044","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593610044?lang=zh_cn&edition=full","pubTime":"2025-12-22 16:32","pubTimestamp":1766392338,"startTime":"0","endTime":"0","summary":"智通财经APP讯，和誉-B(02256)发布公告，2025年12月22日，公司的附属公司上海和誉生物医药科技有限公司(“和誉医药”)宣布，中国国家药品监督管理局(“NMPA”)批准贝捷迈®(盐酸匹米替尼胶囊)，适用于手术切除可能会导致功能受限或出现较严重并发症的症状性腱鞘巨细胞瘤(“TGCT”)成年患者。获批后，默克将尽快推动该产品惠及中国TGCT患者。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1384383.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU2476274720.SGD","BK1161","BK1574","02256","BK1515","09939","IE00B543WZ88.USD","LU2488822045.USD","IE00B5MMRT66.SGD","CSF","IE00BPRC5H50.USD","159938","LU2476274308.USD","LU2778985437.USD"],"gpt_icon":0},{"id":"2593657109","title":"医药外包概念股逆市受压 康龙化成(03759)跌4.14% 机构指美生物安全法案对华CXO企业经营影响有限","url":"https://stock-news.laohu8.com/highlight/detail?id=2593657109","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593657109?lang=zh_cn&edition=full","pubTime":"2025-12-22 14:06","pubTimestamp":1766383579,"startTime":"0","endTime":"0","summary":"金吾财讯 | 医药外包概念股逆市受压，截至发稿，康龙化成 跌4.14%，药明生物跌3.75%，药明康德跌2.89%，昭衍新药跌2.67%，泰格医药跌2.07%，金斯瑞生物科技跌1.36%。招银国际表示，MSCI中国医疗指数2025年初至今累计上涨51.9%，跑赢MSCI中国指数24.3%。近期，医药板块有所回调。政策端方面，《生物安全法案》虽已签署生效，但鉴于其未波及Medicaid和Medicare的采购且对关联方定义明确，以及中国CXO美国行政机构收入占比较小，该机构预计该法案对中国CXO企业实质经营影响有限。","market":"hk","thumbnail":"https://static.szfiu.com/news/20250110/ZDlhMzNiODA0MWQ5OWM0NDQ5YzUxMTZmZWRlMTczNjQ3MzM4NzkwNQ==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250110/ZDlhMzNiODA0MWQ5OWM0NDQ5YzUxMTZmZWRlMTczNjQ3MzM4NzkwNQ==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1972004","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HK0000320223.HKD","09939","LU1242518931.SGD","LU0326950275.SGD","BK1589","LU1720050803.USD","LU0516422440.USD","LU3063872942.SGD","LU1046422090.SGD","02269","SG9999002562.SGD","HK0000306701.USD","BK1161","LU0320764599.SGD","SG9999002463.SGD","LU1880383366.USD","01548","300759","BK1141","159938","LU0708995583.HKD","BK1610","BK1574","LU0516423091.SGD","06127","LU0359202008.SGD","LU0051755006.USD","LU0348735423.USD","CXO","03759","LU0359201612.USD","BK1576","LU0456846285.SGD","HK0000306685.HKD","LU2125910500.SGD","LU2039709279.SGD","03347","LU0417516738.SGD","LU0823426308.USD","LU0417516902.SGD","HK0000320264.USD","LU0140636845.USD","LU0516423174.USD","LU0348825331.USD","02359","LU0327786744.USD","BK0216","LU0819121731.USD","LU0572944931.SGD","BK1583"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.kintor.com.cn","stockEarnings":[{"period":"1week","weight":0.0105},{"period":"1month","weight":-0.0448},{"period":"3month","weight":-0.2258},{"period":"6month","weight":0.28},{"period":"1year","weight":0.9794},{"period":"ytd","weight":0.9794}],"compareEarnings":[{"period":"1week","weight":0.0137},{"period":"1month","weight":0.004},{"period":"3month","weight":-0.0251},{"period":"6month","weight":0.0632},{"period":"1year","weight":0.2846},{"period":"ytd","weight":0.2871}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"开拓药业有限公司是一家主要从事创新药产品研发的投资控股公司。该公司产品致力于解决未满足临床需求的疾病领域，管线主要涵盖皮科（如脱发、痤疮等）及肿瘤适应症。该公司在皮科领域有两款核心药物KX-826及GT20029。该公司在其他疾病领域包括转移性去势抗性前列腺癌（mCRPC）、肝癌、特发性肺纤维化、恶性血液疾病及多种实体瘤等。","yearOnYearQuotes":[{"month":1,"riseRate":0.4,"avgChangeRate":-0.063412},{"month":2,"riseRate":0.8,"avgChangeRate":0.219909},{"month":3,"riseRate":0.4,"avgChangeRate":0.084454},{"month":4,"riseRate":0.6,"avgChangeRate":0.421119},{"month":5,"riseRate":0.6,"avgChangeRate":0.045244},{"month":6,"riseRate":0.333333,"avgChangeRate":-0.066873},{"month":7,"riseRate":0.666667,"avgChangeRate":0.132768},{"month":8,"riseRate":0.166667,"avgChangeRate":-0.071497},{"month":9,"riseRate":0.333333,"avgChangeRate":-0.129033},{"month":10,"riseRate":0.166667,"avgChangeRate":-0.103242},{"month":11,"riseRate":0.666667,"avgChangeRate":0.073526},{"month":12,"riseRate":0.166667,"avgChangeRate":-0.189069}],"exchange":"SEHK","name":"开拓药业-B","nameEN":"KINTOR PHARMA-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"开拓药业-B(09939)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供开拓药业-B(09939)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"开拓药业-B,09939,开拓药业-B股票,开拓药业-B股票老虎,开拓药业-B股票老虎国际,开拓药业-B行情,开拓药业-B股票行情,开拓药业-B股价,开拓药业-B股市,开拓药业-B股票价格,开拓药业-B股票交易,开拓药业-B股票购买,开拓药业-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"开拓药业-B(09939)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供开拓药业-B(09939)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}